Go Pro
NASDAQ:IRD

Opus Genetics Q1 2025 Earnings Report

Opus Genetics logo
$3.98 -0.14 (-3.28%)
As of 11:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Opus Genetics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.34
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$4.30 million
Expected Revenue
$4.00 million
Beat/Miss
Beat by +$302.00 thousand
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Opus Genetics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Opus Genetics Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Opus Genetics Q3 EPS Raised by Brookline Capital Markets
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile